17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Autofluorescence indexes as biomarkers for antiangiogenic loading dose outcome in diabetic macular edema

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose:

          To evaluate the combination of fundus autofluorescence results with several clinical and structural variables into mathematical indexes to enhance their ability to predict visual and anatomical changes after the antivascular endothelial growth factor loading dose.

          Methods:

          Patients with diabetic macular edema were enrolled. Each patient had a comprehensive ophthalmological examination, contrast sensitivity, optical coherence tomography, and fundus autofluorescence assessment. All patients received three monthly doses of ziv-aflibercept and were followed each month for response assessment. Autofluorescence was classified according to its level into five grades. The grades were combined with other variables (best-corrected visual acuity, contrast sensitivity, central macular thickness, macular cube volume, and macular cube average thickness) into normalized indexes. Statistical assessment was done using a Spearman’s rank correlation coefficient, linear regression, and interobserver-agreement analysis.

          Results:

          There was a strong correlation between the fundus autofluorescence/baseline best-corrected visual acuity index and the fundus autofluorescence/contrast-sensitivity index at baseline with the best-corrected visual acuity after the third dose of ziv-aflibercept ( r s  = −0.78, p = .000 and r s  = −0.68, p = .0009 respectively). The fundus autofluorescence/baseline best-corrected visual acuity index and the fundus autofluorescence/contrast-sensitivity index, both at baseline had a mild correlation with the macular volume at 1 month of follow-up ( r s  = 0.56, p = .008 and ( r s  = 0.64, p = .002, respectively).

          Conclusion:

          This study suggests that it is possible to combine fundus autofluorescence results with functional and structural variables into normalized indexes that could potentially predict outcomes after antivascular endothelial growth factor loading dose in patients with diabetic macular edema.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: not found

          Quantitative measurements of autofluorescence with the scanning laser ophthalmoscope.

          To evaluate the feasibility and reliability of a standardized approach for quantitative measurements of fundus autofluorescence (AF) in images obtained with a confocal scanning laser ophthalmoscope (cSLO).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Quantitative fundus autofluorescence in healthy eyes.

            Fundus autofluorescence was quantified (qAF) in subjects with healthy retinae using a standardized approach. The objective was to establish normative data and identify factors that influence the accumulation of RPE lipofuscin and/or modulate the observed AF signal in fundus images.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Clinical applications of fundus autofluorescence in retinal disease

              Fundus autofluorescence (FAF) is a non-invasive retinal imaging modality used in clinical practice to provide a density map of lipofuscin, the predominant ocular fluorophore, in the retinal pigment epithelium. Multiple commercially available imaging systems, including the fundus camera, the confocal scanning laser ophthalmoscope, and the ultra-widefield imaging device, are available to the clinician. Each offers unique advantages for evaluating various retinal diseases. The clinical applications of FAF continue to expand. It is now an essential tool for evaluating age related macular degeneration, macular dystrophies, retinitis pigmentosa, white dot syndromes, retinal drug toxicities, and various other retinal disorders. FAF may detect abnormalities beyond those detected on funduscopic exam, fluorescein angiography, or optical coherence tomography, and can be used to elucidate disease pathogenesis, form genotype-phenotype correlations, diagnose and monitor disease, and evaluate novel therapies. Given its ease of use, non-invasive nature, and value in characterizing retinal disease, FAF enjoys increasing clinical relevance. This review summarizes common ocular fluorophores, imaging modalities, and FAF findings for a wide spectrum of retinal disorders.
                Bookmark

                Author and article information

                Contributors
                Journal
                Ther Adv Ophthalmol
                Ther Adv Ophthalmol
                OED
                spoed
                Therapeutic Advances in Ophthalmology
                SAGE Publications (Sage UK: London, England )
                2515-8414
                25 August 2020
                Jan-Dec 2020
                : 12
                : 2515841420942662
                Affiliations
                [1-2515841420942662]Retina Department, Clínica David, Unidad oftalmológica y Facultad de Medicina, Universidad Michoacana de San Nicolás de Hidalgo, García de León 598-2, Colonia Nueva Chapultepec, CP 58280, Morelia, Michoacán, Mexico
                [2-2515841420942662]Universidad Anáhuac School of Medicine, Mexico City, México
                [3-2515841420942662]Retina Department, Clínica David, Unidad oftalmológica, Morelia, México
                [4-2515841420942662]Laboratorio de Proteómica y Metabolómica, División de investigación, Hospital General de Mexico “Dr. Eduardo Liceaga,” Mexico City, Mexico
                [5-2515841420942662]Ophthalmology Department, Hospital Juárez de México, Mexico City, Mexico
                [6-2515841420942662]Ophthalmology Department, University Hospital “Dr. José E. González,” Monterrey, Mexico
                [7-2515841420942662]Universidad Anáhuac, School of Medicine, Mexico City, México
                [8-2515841420942662]Retina Department, Asociacion para Evitar la Ceguera en Mexico IAP, Mexico City, Mexico
                Author notes
                Author information
                https://orcid.org/0000-0001-5882-3462
                https://orcid.org/0000-0002-6457-4578
                Article
                10.1177_2515841420942662
                10.1177/2515841420942662
                7450463
                fee4ddf3-e979-43c0-95e5-5a08a94bc68b
                © The Author(s), 2020

                This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ( https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages ( https://us.sagepub.com/en-us/nam/open-access-at-sage).

                History
                : 11 February 2020
                : 19 June 2020
                Categories
                Case Series
                Custom metadata
                January-December 2020
                ts1

                antivascular endothelial growth factor therapy,diabetic macular edema,fundus autofluorescence,optical coherence tomography,ziv-aflibercept

                Comments

                Comment on this article